Posaconazole Intravenous (IV) Solution bulk supplier for pharma manufacturers

Posaconazole Intravenous (Iv) Solution Suppliers & Bulk Manufacturers

Available Forms: Intravenous (IV) solution

Available Strengths: 300 mg/100 mL

Reference Brands: Noxafil(US & EU)

Category: Anti-fungal

Posaconazole IV inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and fungal cell membrane formation. It provides broad-spectrum antifungal activity, rapid systemic absorption, and excellent tissue penetration. Benefits include effective treatment of invasive fungal infections, reliable intravenous delivery, and high bioavailability, crucial for managing severe fungal diseases. Posaconazole Intravenous (IV) Solution is available in Intravenous (IV) solution and strengths such as 300 mg/100 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Posaconazole Intravenous (IV) Solution is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Posaconazole Intravenous (IV) Solution can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Posaconazole IV is approved in the EU and US for treating invasive fungal infections. In the EU, MSD’s Noxafil IV is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical data, biosimilarity assessments, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for initial approval and continued safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz. We support efficient market access for posaconazole IV formulations, ensuring adherence to European and American standards for safe, effective antifungal therapy.

Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Posaconazole is used to prevent and treat serious fungal infections, particularly in immunocompromised patients such as those with hematologic malignancies or stem-cell transplants. It is effective against invasive aspergillosis, mucormycosis, and infections caused by Candida species. It is commonly used when patients cannot tolerate or do not respond to other antifungal therapies.

Posaconazole contains the active triazole antifungal compound posaconazole. The formulation includes pharmaceutical excipients that enhance absorption and maintain stability, depending on the dosage form used.

The main trade name for posaconazole is Noxafil, recognized in the USA, EU, UK, and many international markets.

Noxafil (posaconazole) is manufactured by Merck & Co. Generic versions may also be produced by other GMP-certified pharmaceutical companies in different regions.

The generic name is posaconazole.

The primary brand name is Noxafil.

Posaconazole is manufactured in Merck’s regulated facilities located in the USA and Europe, along with various GMP-approved global manufacturers producing generic posaconazole for international distribution.

Yes, Posaconazole Intravenous (IV) Solution is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Posaconazole Intravenous (IV) Solution is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Natamycin

Strength:
5%

Form: Ophthalmic Solution

Reference Brands: Natacyn (USA/EU)

View Details
Naftifine Hydrochloride

Strength:
1 %, 2%

Form: Cream / Gel

Reference Brands: Naftin (USA), Xolafin (USA)

View Details
Miltefosine

Strength:
10 mg, 50 mg

Form: Capsules

Reference Brands: Impavido (USA/EU)

View Details
Sertaconazole Nitrate

Strength:
2 %

Form: Creams

Reference Brands: Ertaczo (USA), Zalain (EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.